Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

372
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
372
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

357
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
357
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.8K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K
Angina V: Nursing Management01:20

Angina V: Nursing Management

457
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
457
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Angina II: Classification01:27

Angina II: Classification

506
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
506

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial commentary: Polypills: Common garden variety or precision formulated for improving cardiovascular outcomes: An ongoing challenge.

Trends in cardiovascular medicine·2022
Same author

TEE-Guided Percutaneous Aspiration of a Large Lead-Associated Vegetation Prior to Transvenous Lead Extraction.

CASE (Philadelphia, Pa.)·2021
Same author

Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction.

The American journal of cardiology·2021
Same author

Utilization of guideline-directed medical therapy in patients with de novo heart failure with reduced ejection fraction: A Veterans Affairs study.

Journal of family medicine and primary care·2020
Same author

Atrial Fibrillation Catheter Ablation: Overcoming Complications and Improving Success.

The Journal of innovations in cardiac rhythm management·2020
Same author

Ventricular Arrhythmias in the Patient with a Structurally Normal Heart.

The Journal of innovations in cardiac rhythm management·2020

Related Experiment Video

Updated: Mar 8, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.8K

Drug Therapy for Stable Angina Pectoris.

Talla A Rousan1, Sunil T Mathew1, Udho Thadani2

  • 1The University of Oklahoma Health Sciences Center and The Veteran Affairs Medical Center, 920 Stanton L. Young Blvd., WP 3010, Oklahoma City, OK, 73104, USA.

Drugs
|January 26, 2017
PubMed
Summary

Managing chronic stable angina requires personalized drug therapy, considering patient comorbidities and circulatory status, not just guideline-based approaches. Evidence-based selection of anti-anginal medications is crucial for improving quality of life.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.4K

Related Experiment Videos

Last Updated: Mar 8, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.8K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.4K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic stable angina is chest discomfort caused by myocardial ischemia during exertion.
  • It impacts quality of life and is linked to coronary artery disease or normal coronary arteries.
  • Current guideline-based anti-anginal drug choices lack robust evidence.

Purpose of the Study:

  • To offer a guideline-based and individual-based approach to stable angina drug therapy.
  • To emphasize personalized treatment considering circulatory status and comorbidities.
  • To focus on drug therapy, excluding revascularization for stable angina.

Main Methods:

  • Review of current literature and treatment guidelines for stable angina.
  • Analysis of factors influencing drug therapy decisions, including comorbidities.
  • Discussion of evidence-based and individualized treatment strategies.

Main Results:

  • Guideline recommendations for anti-anginal drug selection are not consistently evidence-based.
  • Personalized treatment approaches are necessary for effective angina management.
  • Aspirin and statins are recommended for patients with angina and coronary artery disease.

Conclusions:

  • Optimal drug therapy for stable angina requires a personalized approach beyond standard guidelines.
  • Further research is needed for treating patients with angina and normal coronary arteries.
  • Individualized treatment decisions should integrate patient-specific factors for better outcomes.